Page 6 - John Bluth News Today

Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France News Provided By Share This Article For investors and media only RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) has granted an Autorisation Temporaire dUtilisation de cohorte (cohort ATU), or Temporary Authorization for Use, for the use of berotralstat to prev...

Operator Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst fourth-quarter 2020 earnings call. [Operator instructions] Please be advised at todays conference is being recorded. [Operator instructions] I would now like to hand the conference over to your speaker today, Mr. John Bluth, with BioCryst. You may begin. Senior Vice President, Investor Relations and Corporate Communications Thanks, Daphne. Good morning, and welcome to BioCrysts fourth-quarter 2020 corporate up...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioCryst to Present at Upcoming Investor Conferences BioCryst Pharmaceuticals, Inc.February 18, 2021 GMT RESEARCH TRIANGLE PARK, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Cowen 41st Annual Healthcare Conference on Thursday, March 4, 2021 at 12:10 p.m. ET and the Barclays Annual Healthcare Conference on Thur...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Share: RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for oral, once-daily ORLADEYO ™ (berotralstat) 150 mg for prophylactic treatment of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older. ORLADEYO is the first and only prophylactic HAE medication approved in Japan. One caps...

Share: —  —EMPOWER Patient Services providing streamlined, single point of contact access to therapy and reimbursement support—  RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that oral, once-daily ORLADEYO™ (berotralstat) is now available for shipment to patients with a prescription in the United States. ORLADEYO was approved by the U.S. Food and Drug Administration (FDA) on December 3, 2020 for prop...